| Name | Title | Contact Details |
|---|
We are a clinical-stage biopharmaceutical company focused on changing the lives of patients living with nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. Our teams in the US and Israel are developing highly differentiated medicines that address unmet medical needs based on robust research. Our lead product candidate, BIO89-100, is a novel long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue.
InCarda Therapeutics is a clinical stage drug delivery company pioneering a novel approach of treating cardiovascular diseases and conditions by the inhalation route.
New Hampshire Department of Resources and Economic Development is a Concord, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
VLST is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Scrippshealth is a Lajolla, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.